BioSpace News Archive

Ultimovacs ASA presented clinical endpoints and biomarker results from patients in the UV1-103 phase I trial, at the 19th International Conference of the Society for Melanoma Research, being held 17-20 October in Edinburgh, UK.

EditForce, Inc., headquartered in Fukuoka, Japan, has realized the world’s first RNA-editing technology that enables RNA-editing bases to be changed from “U” to “C,” and demonstrated that this technology works even in human cells in a joint study with Professor Takahiro Nakamura, Faculty of Agriculture, Kyushu University.

Midatech Pharma announces that further to the Company’s announcement on 14 April 2022, it has received written notification dated 10 October 2022 from The NASDAQ Stock Market LLC that for 10 consecutive business days, from 26 September 2022 to 9 October 2022, the closing bid price of the Company’s American Depositary Shares had been at $1.00 per share or greater and, accordingly, the Company has regained compliance with NASDAQ Listing Rule 5550.

ANGLE plc, a world-leading liquid biopsy company, announces that the Board has taken the decision to close the Company’s facilities in Toronto, Canada in an orderly wind down.

AlzeCure Pharma announced that an abstract on NeuroRestore ACD856 and its potential disease-modifying properties has been accepted for presentation at the annual Alzheimer’s conference CTAD, Clinical Trials in Alzheimer’s Disease, which this year is being held in San Francisco, November 29 - December 2.

Biovica International The shareholders of Biovica International AB, reg. no. 556774-6150, are hereby invited to the extra general meeting to be held on Monday 7 November 2022, at 13.00 CET at Baker & McKenzie Advokatbyrå’s premises at Vasagatan 7 in Stockholm.

Invitation to attend Vitrolife AB conference call regarding presentation of the interim report January - September 2022.

Illumina Inc., a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative genomics company, announced a partnership to accelerate progress to end tuberculosis worldwide.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced participation in the 2022 PDA Universe of Pre-Filled Syringes and Injection Devices Conference to showcase its leadership and expertise on industry challenges and trends in packaging and containment.

IDEAYA Biosciences, Inc. announced clinical program updates for IDE397, an investigational, potential best-in-class, small molecule MAT2A inhibitor being evaluated in an ongoing Phase 1/2 clinical trial.